Biomarkers have been shown to improve drug approval rates by 2-10x. Our services help you scale your biomarker discovery capacity beyond genomics, enabling large-scale identification, validation, and translation of dynamic biomarkers for precision-guided drug development.
Thousands of metabolites, lipids, and proteins can be captured per sample, across thousands of samples at a time, scaling down to single quantitative measures.
Our high throughput capacity generates insights at scale, including an integrative biocomputational framework to map key biomarkers and their associations.
We tap our longitudinal DynamiQ™ database of multi-dimensional measures in tens of thousands of biosamples to cross-validate discoveries in independent human samples.
From early discovery to clinical development, including CLIA assays, we can provide multi-omics services to support your drug candidate’s efficient advancement through the R&D pipeline.
Our services are disease- and drug modality-agnostic, spanning the entire drug development spectrum from profiling cells and media, to preclinical models, through to clinical implementation in Phase I, II, III and even Phase IV programs.
Our technologies and approaches can be applied in many different ways to de-risk development and accelerate promising drugs, with the ultimate goal of identifying biomarkers that can be used to align the right patient, with the right disease, with the right therapy.
The vast majority of biomarker discovery for drug development has focused on genomics, yet >80% of disease risk is non-genetic.
With large-scale profiling of small molecule biomarkers, which read out genetic and non-genetic influences, we can help you improve disease understanding and in turn, the precision and efficacy of treatments.
Sapient’s state-of-the-art mass spectrometry enables high-confidence protein annotations in plasma, CSF, saliva, urine, tissue, and cells, optimizing for coverage and throughput to best suit your study requirements at each phase.
Our methods are scalable from nontargeted discovery, measuring as many as 12,000 protein groups per sample, to single quantitative clinical protein assays.
We offer biopharma customers the collaborative expertise of our data science team, who are skilled in integrative analyses of large-scale, multi-omics datasets.
They help to interpret the data we generate to identify biologically significant biomarkers of interest, for example of target engagement or responders vs. non-responders. They can also extend insight delivery via Sapient’s DynamiQ Insights Engine for at-scale analyses of biomarker dynamics over time.
Precision medicine often requires tailored approaches. We can often provide solutions for difficult-to-measure biomarkers, or will work with you to define the ideal profiling approach based on your samples and study objectives.
Through our CLIA-certified, CAP-accredited clinical laboratory, we can also support the development of CLIA assays.
